Has Mark Wiesen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $460 in general payments to Mark Wiesen, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Wiesen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Wiesen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Wiesen, MD

Endocrinology, Diabetes & Metabolism · Teaneck, NJNPI 1053367912

Payments from drug & device makers

$460in general payments, 2019–2025

Across 16 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$229
Sanofi-aventis U.S. LLC$80
Medtronic$55
Valeritas, Inc.$49
Insulet Corporation$36
Lilly USA, LLC$12

What the payments were for

Food & beverage$44997%
Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	2	$229
Sanofi-aventis U.S. LLC	6	$80
Medtronic	2	$55
Valeritas, Inc.	3	$49
Insulet Corporation	2	$36
Lilly USA, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EVENITY$229

How this compares

$460 in reported general payments places this provider in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024

$343,906

Medicare patients

899

Services billed

12,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MounjaroTirzepatide	386	$555,163
OzempicSemaglutide	291	$465,093
JardianceEmpagliflozin	183	$248,391
Tresiba Flextouch U-200Insulin Degludec	129	$226,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	115	$189,237
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	112	$107,859
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	104	$102,774
RybelsusSemaglutide	61	$102,614
Tresiba Flextouch U-100Insulin Degludec	84	$91,216
FarxigaDapagliflozin Propanediol	59	$78,191
Humalog Kwikpen U-200Insulin Lispro	34	$76,369
TrulicityDulaglutide	43	$70,943
JanuviaSitagliptin Phosphate	59	$60,602
Humalog Kwikpen U-100Insulin Lispro	178	$57,991
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	71	$43,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog	$12	$646,554503 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Teaneck

Atara SchultzTeaneck$357K
Barry GertzRahway$903K
Nawras MakhsidaRandolph$882K
Marc SandbergFlemington$567K
Joanne WaldstreicherNew Brunswick$441K
Gregory BaroneCherry Hill$433K
Taher ModarressiPennington$414K
Navtika DesaiHillsborough$408K
Anthony CannonTurnersville$296K
Sunil AsnaniBrick$295K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →